Nycomed, Neurochem gang up on Alzheimer’s

August 8, 2001

Nycomed and Neurochem have struck an alliance aimed at developing novel technologies for the diagnosis of Alzheimer’s disease. Using Neurochem’s proprietary molecules as a basis, the two companies will work on the design and selection of a

Nycomed and Neurochem have struck an alliance aimed at developing novel technologies for the diagnosis of Alzheimer’s disease. Using Neurochem’s proprietary molecules as a basis, the two companies will work on the design and selection of a product to detect the presence of amyloid plaques that accumulate in the brains of Alzheimer’s patients.